

March 16, 2015



POXEL: 2015 Financial Calendar

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL (Paris:POXEL) (Euronext - FR0012432516), an independent French biopharmaceutical company focused on the development of antidiabetic drugs, today announces its schedule for the publication of financial information for 2015.

Événement	Date *
2014 Full-Year Sales	March 16, 2015
2014 Full-Year Financial statements	April 30, 2015
2015 Q1 Sales	May 5, 2015
Annual Shareholders' Meeting	June 16, 2015
2015 Q2 Sales	July 15, 2015
2015 June 30 th , Financial statements	August 31, 2015
2015 Q3 Sales	October 22, 2015
2015 Full-Year Sales	January 28, 2016

** Subject to modification. Press releases are published after market closes.*

About Poxel

Poxel uses its unique development expertise in metabolism to advance a pipeline of truly novel products currently focused on type 2 diabetes. Our first-in-class lead product, Imeglimin, targeting mitochondrial dysfunction, has successfully completed Phase 2 development in the US and EU and has entered clinical development in Japan. We are advancing our second program, PXL770, a direct AMPK activator, through clinical proof-of-concept. We will generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

Investor / Media Relations - France

NewCap

Florent Alba/Nicolas Merigeau

poxel@newcap.fr

+33 1 44 71 98 55

or

Investor / Media Relations – EU/US

MacDougall Biomedical Communications

Gretchen Schweitzer or Anca Alexandru
aalexandru@macbiocom.com
+49 89 2424 3494

Source: POXEL